Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Immunotherapy delays deterioration in health-related quality of life in metastatic NSCLC

Presented By

Dr Edward Garon, David Geffen School of Medicine at UCLA, CA, USA

Trial

Phase 3, POSEIDON

Conference

ELCC 2022

25 May, 2022 12:36

Characteristics of long-term survivors in the CASPIAN trial

Presented By

Dr Niels Reinmuth, Asklepios Lung Clinic, Germany

Trial

Phase 3, CASPIAN

Conference

ELCC 2022

25 May, 2022 12:34

ELCC 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ELCC 2022

19 April, 2022 10:43

HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC

Presented By

Prof. Ghassan Abou-Alfa, Memorial Sloan Kettering Center, NY, USA

Trial

Phase 3, HIMALAYA

Conference

ASCO GI 2022

21 March, 2022 10:05

ASCO GI 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ASCO GI 2022

8 February, 2022 12:37

Three-year OS follow-up from CASPIAN trial

Presented By

Dr Luis Paz-Ares, Hospital Universitario 12 de Octubre, Spain

Trial

Phase 3, CASPIAN

Conference

ESMO 2021

19 November, 2021 09:32

Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma

Presented By

Prof. Thomas Powles, Barts Cancer Centre, London, UK

Trial

Phase 3, DANUBE

Conference

EAU 2021

31 August, 2021 12:26

ES-SCLC: CASPIAN trial perspectives from Prof. Jonathan Goldman

Presented By

Prof. Jonathan Goldman, Prof. Luis Paz-Ares

Trial

Phase 3, CASPIAN

Journal

Physician Weekly

Conference

ASCO Annual Meeting 2020

13 April, 2021 16:27

Better prediction of favourable responses to immune checkpoint inhibitors in mUC

Presented By

Dr Marie Alt, Princess Margaret Cancer Centre, Canada

Conference

ASCO GU 2021

24 March, 2021 15:02

First-line immune-combination therapies in mUC

Trial

Phase 3, KEYNOTE-361

Conference

ESMO 2020

25 November, 2020 14:43

ES-SCLC: tremelimumab + durvalumab + chemotherapy misses endpoint

Presented By

Prof. Luis G. Paz-Ares, Hospital 12 de Octubre, Spain

Trial

Phase 3, CASPIAN

Conference

ASCO 2020

8 September, 2020 13:50

Durvalumab added to etoposide improves outcomes in ES-SCLC

Trial

CASPIAN

Conference

WCLC 2019

8 November, 2019 23:06

I-O monotherapy

Presented By

Prof. Martin Reck, Airway Research Center North, Grosshansdorf, Germany

Trial

CheckMate 026, Keynote-024, Checkmate 227, MYSTIC, B-F1RST

Conference

ELCC 2019

25 June, 2019 23:13

Post-study immunotherapy in MYSTIC

Presented By

Dr Niels Reinmuth, Asklepios Lung Clinic, Munich-Gauting, Germany

Trial

Phase 3, MYSTIC

Conference

ELCC 2019

25 June, 2019 13:26

Medical Conferences

Tag: Tremelimumab